Navigating Together for a Better Tomorrow
How Quasar Is Responding to COVID-19 and Its Effect On Businesses
As the coronavirus pandemic continues to change the world, we’re all navigating through uncertainty.
At Quasar, we embrace our “philosophy of operational excellence”. This means that even in times of struggle, we have an operational focused effort. While our number one concern is the health and safety of our employees and our community, we are also here to assist you with business continuity, even in these uncertain times.
How We're Helping
Meeting all Q-2 commitments and more.
We are here to support the medical device companies globally who have been affected by the pandemic and thus facing challenges to meet previously set production goals. To ensure we are in a position to to support your production needs, we have EXPANDED Manufacturing Capacity in the following areas:
ISO/FDA Registered Facilities
+30k sqft ISO 7/8 Clean Rooms at our ISO/FDA Registered Facilities in China, Hong Kong, and Thailand.
with additional capacity to support Class II & III devices.
Critical Backorders recovery plan
Commercial and Manufacturing teams at the ready to assist with evaluating and developing a recovery plan for you.
Commercial, Quality and Supply Chain teams at the ready to assist with your supplier qualification and approval process to qualify a second source.
Commercial, Quality and Engineering teams at the ready to assist with validation and transfer plans to support a manufacturing transfer project.
Emergency Action Plans
Quasar can assist with developing an emergency (mitigation) action plan to avoid future disruptions to your supply chain.
In addition to the regulatory requirement, post-market surveillance offers an opportunity for collecting market data that can provide valuable insight into the device improvement. In this article, we cover some of the tremendous value that can be created both on the business side and the engineering side when post-market surveillance is done correctly for your medical device.
We rely on these best practices for the most efficient change control board process. This ensures that the medical devices we produce are constantly improving and meeting customers’ demands while also continuously meeting existing safety and quality standards.
How Quasar was able to ensure the safe return of over 1,300 employees with zero cases of infection found and resumed operations in just 3 weeks.
In addition to the regulatory requirement, post-market surveillance offers an opportunity for collecting market data that can provide valuable... read more
We rely on these best practices for the most efficient change control board process. This ensures that the medical... read more
How Quasar was able to ensure the safe return of over 1,300 employees with zero cases of infection found... read more